IDO1 regulating ROS rhythm reveals glycogenolysis/PPP as a cancer treatment target.

Disruption of ROS rhythm through dual inhibition of IDO1 and AhR significantly prolongs survival in NSG mice with tumors.

• Why it matters: Understanding how ROS rhythmicity influences tumor growth and therapy response is crucial, as its loss in hypoxic tumor microenvironments may promote tumor progression and resistance.
• What they did: The study examined ROS oscillations and IDO1 activity in cancer cells, revealing that low ROS levels promote IDO1 degradation, while high ROS levels activate IDO1 to clear ROS, and that hypoxia shifts tumor cells to glycogenolysis pathways.
• The result: Targeting both IDO1 and AhR pathways enforces disruption of ROS rhythm, which may serve as an effective therapeutic strategy to inhibit tumor growth and improve survival outcomes.